Antibodies to the Protein Tyrosine Phosphatases IAR and IA-2 are Associated with Progression to Insulin-Dependent Diabetes (IDDM) in First-Degree Relatives At-Risk for IDDM

References

• Harrison L. C. Islet cell antigens in insulin-dependent diabetes: Pandora's box revisited. Immunol. Today 1992; 13: 348–352
   PubMedGoogle Scholar
• Rabin D. U., Pleasic S. M., Shapiro J. A., Yoo-Warren H., Oles J., Hicks J. M., et al. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J. Immunol 1994; 152: 3183–3187
   PubMed Web of Science ®Google Scholar
• Lan M. S., Lu J., Goto Y., Notkins A. L. Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. DNA Cell Biol 1994; 13: 505–514
   PubMed Web of Science ®Google Scholar
• Landin Olsspn M., Karlsson A., Dahlquist G., Blom L., Lernmark Å, Sundkvist G. Islet cell and other organ-specific autoantibodies in all children developing type 1 (insulin-dependent) diabetes mellitus in Sweden during one year and in matched control children. Diabetologia 1989; 32: 387–395
   PubMed Web of Science ®Google Scholar
• Hagopian W. A., Sanjeevi C. B., Kockum I., Landin-Olsson M., Karlsen A. E., Sundkvist G., et al. Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children. J. Clin. Invest 1995; 95: 1505–1511
   PubMed Web of Science ®Google Scholar
• Gorsuch A. N., Spencer K. M., Lister J., McNally J. M., Dean B. M., Bottazzo G. F., et al. Evidence for a long prediabetic period in type 1 (insulin-dependent) diabetes mellitus. Laneet 1995; 2: 1363–1365
   Google Scholar
• DeAizpurua H. J., Wilson Y. M., Harrison L. C. Glutamic acid decarboxylase autoantibodies in preclinical insulin-dependent diabetes. Proc. Natl. Acad. Set. USA 1992; 89: 9841–9845
   PubMed Web of Science ®Google Scholar
• Verge C. F., Silink M., Howard N. J. The incidence of childhood IDDM in New South Wales, Australia. Diabetes Care 1994; 17: 693–696
   PubMed Web of Science ®Google Scholar
• Bingley P. J., Bonifacio E., Gale E. A.M. Can we really predict IDDM. Diabetes 1993; 42: 213–220
   PubMed Web of Science ®Google Scholar
• Verge C. F., Gianani R., Kawasaki E., Yu L., Pietropaolo M., Jackson R. A., et al. Prediction of type 1 diabetes in first-degree relatives using a combination of insulin, GAD and ICA512bdc/IA-2 autoantibodies. Diabetes 1996; 45: 926–933
   PubMed Web of Science ®Google Scholar
• Ziegler A. G., Ziegler R., Vardi P., Jackson R. A., Soeldner J. S., Eisenbarth G. S. Life-table analysis of progression to diabetes of anti-insulin autoantibody-positive relatives of individuals with type I diabetes. Diabetes 1989; 38: 1320–1325
   PubMed Web of Science ®Google Scholar
• Gianani R., Rabin D. U., Verge C. F., Yu L., Babu S. R., Pietropaolo M., et al. ICA512 autoantibody radioassay. Diabetes 1995; 44: 1340–1344
   PubMed Web of Science ®Google Scholar
• Solimena M., Dirkx R., Jr, Hermel J. M., Pleasic-Williams S., Shapiro J. A., Caron L., et al. ICA 512, an autoantigen of type 1 diabetes, is an intrinsic membrane protein of neurosecretory granules. EMBO J 1996; 15: 2102–2114
   PubMed Web of Science ®Google Scholar
• Bonifacio E., Lampasona V., Genovese S., Ferrari M., Bosi E. Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40 K autoantigen and a target of islet-cell antibodies. J. Immunol 1995; 155: 5419–5426
   PubMed Web of Science ®Google Scholar
• Passini N., Larigan J. D., Genovese S., Appella E., Sinigaglia F., Rogge L. The 37/40-kilodalton autoantigen in insulin-dependent diabetes mellitus is the putative tyrosine phosphatase IA-2. Proc. Natl. Acad. Sci. 1995; 92: 9412–9416
   PubMed Web of Science ®Google Scholar
• Payton M. A., Hawkes C. J., Christie M. R. Relationship of the 37,000- and 40,000-Mr tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). J. Clin. Invest 1995; 96: 1506–1511
   PubMed Web of Science ®Google Scholar
• Christie M. R., Vohra G., Champagne P., Daneman D., Delovitch T. L. Distinct antibody specificities to a 64-kD islet cell antigen in type 1 diabetes as revealed by trypsin treatment. J. Exp. Med. 1990; 172: 789–794
   PubMed Web of Science ®Google Scholar
• Chiang M. K., Flanagan J. G. PTP-NP, a new member of the receptor protein tyrosine phosphatase family, implicated in development of nervous system and pancreatic endocrine cells. Development 1996; 122: 2239–2250
   PubMed Web of Science ®Google Scholar
• Lu J., Li Q., Xie H., Chen Z. J., Borovitskaya A. E., Maclaren N. K., et al. Identification of a second transmembrane protein tyrosine phosphatase, IA-2β, as an auto-antigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Proc. Nail. Acad. Sci. USA 1996; 93: 2307–2311
   PubMed Web of Science ®Google Scholar
• Wasmeier C., Hutton J. C. Molecular cloning of phogrin, a protein-tyrosine phosphatase homologue localized to insulin secretory granule membranes. J. Biol. Chem 1996; 271: 18161–18170
   Google Scholar
• Cui L., Yu W. P., DeAizpurua H. J., Schmidli R. S., Pallen C. J. Cloning and characterization of IAR, a novel receptor-like protein tyrosine phosphatase and autoantigen in insulin-dependent diabetes. J. Biol. Chem 1996; 271: 24817–24823
   PubMed Web of Science ®Google Scholar
• Kawasaki E., Hutton J. C., Eisenbarth G. S. Molecular cloning and characterization of the human transmembrane protein tyrosine phosphatase homologue, phogrin, an autoantigen of type I diabetes. Biochem. Biophys. Res. Comm 1996; 227: 440–447
   PubMed Web of Science ®Google Scholar
• Smith P. D., Barker K. T., Wang J., Lu Y. J., Shipley J., Crompton M. R. ICAAR, a novel member of a new family of transmembrane, tyrosine phosphatase-like proteins. Biochem. Biophys. Res. Comm 1996; 229: 402–411
   PubMed Web of Science ®Google Scholar
• Kawasaki E., Eisenbarth G. S., Wasmeier C., Hutton J. C. Autoantibodies to protein tyrosine phosphatase-like proteins in type I diabetes: overlapping specificities to phogrin and ICA512/IA-2. Diabetes 1996; 45: 1344–1349
   PubMed Web of Science ®Google Scholar
• Hawkes C. J., Wasmeier, Christie M. R., Hutton J. C. Identification of the 37-kDa antigen in IDDM as a tyrosine phosphatase-like protein (phogrin) related to IA-2. Diabetes 1996; 45: 1187–1192
   PubMed Web of Science ®Google Scholar
• Christie M. R., Genovese S., Cassidy D., Bosi E., Brown T. J., Lai M., et al. Antibodies to islet 37 k antigen, but not glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes 1994; 43: 1254–1259
   PubMed Web of Science ®Google Scholar
• Christie M. R., Tun R. Y., Lo S. S., Cassidy D, Brown T. J., Hollands J., et al. Antibodies to GAD and tryptic fragments of islet 64 k antigen as distinct markers for development of IDDM. Diabetes 1992; 41: 782–778
   PubMed Web of Science ®Google Scholar
• Bingley P. J., Christie M. R., Bonifacio E., Bonfanti R., Shattock M., Fonte M. T., et al. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 1994; 43: 1304–1320
   PubMed Web of Science ®Google Scholar
• Bonifacio E., Genovese S., Braghi S., Bazzigaluppi E., Lampasona V., Bingley P. J., et al. Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia 1995; 38: 816–822
   PubMed Web of Science ®Google Scholar
• Bonifacio E., Bingley P. J., Shattock M. Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes. Lancet 1990; 335: 147–149
   PubMed Web of Science ®Google Scholar
• Vardi P., Dib S. A., Tuttleman M., Connelly J. E., Grinbergs M., Radizabeh A., et al. Competitive insulin autoantibody assay. Prospective evaluation of subjects at high risk for development of type I diabetes mellitus. Diabetes 1987; 36: 1286–1291
   PubMed Web of Science ®Google Scholar
• McNair P. D., Colman P. G., Alford F. P., Harrison L. C. Reproducibility of the first-phase insulin response to intravenous glucose is not improved by retrograde cannulation and arterialization or the use of a lower glucose dose. Diabetes Care 1995; 18: 1168–1173
   PubMed Web of Science ®Google Scholar
• Cox D. R. Regression models and life tables (with discussion). J. Royal Stat. Soc. Series B 1972; 34: 187–220
   Web of Science ®Google Scholar
• Vardi P., Crisa L., Jackson R. A. Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia 1991; 34: 93–102
   PubMed Web of Science ®Google Scholar
• Lu J., Notkins A. L., Lan M. S. Isolation, sequence and expression of a novel mouse brain cDNA, mIA-2, and its relatedness to members of the protein tyrosine phosphatase family. Biochem. Biophys. Res. Comm 1994; 204: 30–36
   PubMed Web of Science ®Google Scholar
• Mauch L., Krüger C., Humbel R. L., Bliestle H., Krumm B., Liedvogel B., et al. The intracellular domain of IA-2 is the most suitable for measuring IA-2 autoantibodies. Autoimmunity 1996; 24(Suppl. 1)10
   Google Scholar
• Hagopian W. A., Michelsen B., Karlsen A. E. Autoantibodies in IDDM primarily recognize the 65,000-M(r) rather than the 67,000-M(r) isoform of glutamic acid decarboxylase. Diabetes 1993; 42: 631–636
   PubMed Web of Science ®Google Scholar